• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

FDA Denies Outlook’s Wet AMD Bid, Issues Complete Response Letter

cafead

Administrator
Staff member
  • cafead   Aug 30, 2023 at 11:12: AM
via The FDA on Wednesday rejected Outlook Therapeutics’ investigational ophthalmic bevacizumab solution ONS-5010, which the company was proposing as a treatment for wet age-related macular degeneration.

article source